Physician profile
Thomas Ardiles
NPI 1437119278
$46,729.28
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $11K · 2021: $12K · 2023: $121 · 2024: $27.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $148.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $14,770.56 | 2019-2021 | |
| Grifols USA, LLC | $14,601.65 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $10,197.45 | 2019-2021 | |
| Cook Incorporated | $2,800.00 | 2019 | |
| Grifols Shared Services North America, INC. | $1,449.36 | 2019-2021 | |
| Stryker Corporation | $1,000.00 | 2020 | |
| Genzyme Corporation | $340.85 | 2019-2020 | |
| Genentech USA, INC. | $279.59 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $158.46 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.35 | 2019-2020 | |
| Abbott Laboratories | $131.51 | 2019 | |
| Abiomed | $124.99 | 2021 | |
| Genentech, INC. | $103.88 | 2019 | |
| Cook Medical LLC | $90.86 | 2019 | |
| Glaxosmithkline, LLC. | $82.02 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $64.29 | 2019-2020 | |
| La Jolla Pharmaceutical Company | $54.14 | 2019 | |
| Getinge USA Sales, LLC | $42.88 | 2023 | Cardiohelp |
| Baxter Healthcare | $42.61 | 2023 | Hillrom - Vest System Model 105 Home Care |
| Octapharma USA, INC. | $35.59 | 2023 | Fibryga, Octaplas, Balfaxar |
| Vapotherm INC | $28.47 | 2019 | |
| Gilead Sciences, INC. | $27.08 | 2024 | |
| United Therapeutics Corporation | $23.57 | 2021 | |
| Shire North American Group INC | $23.24 | 2019 | |
| Astellas Pharma US INC | $20.63 | 2020 | |
| Advanced Respiratory, INC | $20.03 | 2020 | |
| Merck Sharp & Dohme LLC | $18.34 | 2020 | |
| Sandoz INC. | $16.05 | 2019 | |
| Circassia INC. | $15.80 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.17 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $10.86 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Ardiles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.